ABSTRACT
The skeleton is one of the most common sites for metastatic disease, particularly from breast and prostate cancer. Bone metastases are associated with considerable morbidity, and accurate imaging of the skeleton is important in determining the appropriate therapeutic plan. Sodium fluoride labeled with fluorine 18 (sodium fluoride F 18 [(18)F-NaF]) is a positron-emitting radiopharmaceutical first introduced several decades ago for skeletal imaging. (18)F-NaF was approved for clinical use as a positron emission tomographic (PET) agent by the U.S. Food and Drug Administration in 1972. The early use of this agent was limited, given the difficulties of imaging its high-energy photons on the available gamma cameras. For skeletal imaging, it was eventually replaced by technetium 99m ((99m)Tc)-labeled agents because of the technical limitations of (18)F-NaF. During the past several years, the widespread availability and implementation of hybrid PET and computed tomographic (CT) dual-modality systems (PET/CT) have encouraged a renewed interest in (18)F-NaF PET/CT for routine clinical use in bone imaging. Because current PET/CT systems offer high sensitivity and spatial resolution, the use of (18)F-NaF has been reevaluated for the detection of malignant and nonmalignant osseous disease. Growing evidence suggests that (18)F-NaF PET/CT provides increased sensitivity and specificity in the detection of bone metastases. Furthermore, the favorable pharmacokinetics of (18)F-NaF, combined with the superior imaging characteristics of PET/CT, supports the routine clinical use of (18)F-NaF PET/CT for oncologic imaging for skeletal metastases. In this article, a review of the indications, imaging appearances, and utility of (18)F-NaF PET/CT in the evaluation of skeletal disease is provided, with an emphasis on oncologic imaging.
Subject(s)
Bone Neoplasms/diagnosis , Fluorine Radioisotopes , Positron-Emission Tomography , Radiopharmaceuticals , Sodium Fluoride , Tomography, X-Ray Computed , Humans , Image Interpretation, Computer-Assisted , Multimodal Imaging , Positron-Emission Tomography/methods , Radiation Dosage , Technetium Tc 99m Medronate , Tomography, X-Ray Computed/methodsSubject(s)
Dopamine Plasma Membrane Transport Proteins/metabolism , Nortropanes , Nuclear Medicine , Societies, Medical , Tomography, Emission-Computed, Single-Photon/methods , Contraindications , Documentation , Female , Humans , Image Interpretation, Computer-Assisted , Pregnancy , Research Design , Tomography, Emission-Computed, Single-Photon/standardsABSTRACT
Imaging that can detect pathophysiologic change in the brain holds great promise for diagnostic assessment of patients with Alzheimer disease (AD) and dementia. Although a previous metaanalysis centering on literature from 1990 to 2000 showed a summary accuracy of 86% for (18)F-FDG PET for AD diagnosis, the clinical value was considered uncertain because of methodologic shortcomings. Review of the recent literature since 2000 demonstrates that the evidence for (18)F-FDG PET in assessment of dementia has increased with new studies that include autopsy confirmation, wide-diagnostic-spectrum recruitment in primary care settings, historical and prospective cohort studies, and multicenter data analyses. These data support the role of (18)F-FDG PET as an effective and useful adjunct to other diagnostic information in the assessment of patients with symptoms of dementia. Findings are in line with recently revised diagnostic criteria of AD that for the first time recognize the unique role of biomarker evidence in disease definition.
Subject(s)
Dementia/diagnostic imaging , Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Safety , Alzheimer Disease/diagnostic imaging , Alzheimer Disease/metabolism , Alzheimer Disease/pathology , Alzheimer Disease/physiopathology , Dementia/metabolism , Dementia/pathology , Dementia/physiopathology , Fluorodeoxyglucose F18/adverse effects , Fluorodeoxyglucose F18/metabolism , Humans , Positron-Emission Tomography/adverse effects , Positron-Emission Tomography/standards , Reference StandardsABSTRACT
UNLABELLED: Patients with mild traumatic brain injury (TBI) often complain of cognitive fatigue during the chronic recovery phase. The Paced Auditory Serial Addition Test (PASAT) is a complex psychologic measure that may demonstrate subtle deficiencies in higher cognitive functions. The purpose of this study was to investigate the brain activation of regional cerebral blood flow (rCBF) with PASAT in patients with mild TBI to explore mechanisms for the cognitive fatigue. METHODS: Two groups consisting of 15 patients with mild TBI and 15 healthy control subjects underwent (99m)Tc-ethylene cysteine dimer SPECT at rest and during PASAT on a separate day. Cortical rCBF was extracted using a 3-dimensional stereotactic surface projection and statistically analyzed to identify areas of activation, which were compared with PASAT performance scores. RESULTS: Image analysis demonstrated a difference in the pattern of activation between patients with mild TBI and healthy control subjects. Healthy control subjects activated the superior temporal cortex (Brodmann area [BA] 22) bilaterally, the precentral gyrus (BA 9) on the left, and the precentral gyrus (BA 6) and cerebellum bilaterally. Patients with mild TBI demonstrated a larger area of supratentorial activation (BAs 9, 10, 13, and 46) but a smaller area of activation in the cerebellum, indicating frontocerebellar dissociation. CONCLUSION: Patients with mild TBI and cognitive fatigue demonstrated a different pattern of activation during PASAT. Frontocerebellar dissociation may explain cognitive impairment and cognitive fatigue in the chronic recovery phase of mild traumatic brain injury.
Subject(s)
Brain Injuries/diagnosis , Brain Injuries/physiopathology , Brain Mapping/methods , Brain/physiopathology , Cognition Disorders/diagnosis , Cognition Disorders/physiopathology , Neuropsychological Tests , Tomography, Emission-Computed, Single-Photon/methods , Adult , Brain Injuries/complications , Cerebellum/physiopathology , Chronic Disease , Cognition , Cognition Disorders/etiology , Female , Frontal Lobe/physiopathology , Humans , Male , Middle AgedABSTRACT
A woman with papillary thyroid carcinoma treated with surgery and postoperative 131I returned 4 y later for a whole-body survey. The imaging results initially suggested disease recurrence but were later found to be false positive and due to 131I uptake in a necklace that had been contaminated by the patient's saliva. This case stresses the importance of having the patient remove all jewelry before undergoing a radioiodine survey.
Subject(s)
Artifacts , Diagnostic Errors/prevention & control , Iodine Radioisotopes/therapeutic use , Neoplasm Recurrence, Local/prevention & control , Thyroid Neoplasms/diagnostic imaging , Thyroid Neoplasms/radiotherapy , Whole-Body Counting/methods , Adult , False Positive Reactions , Female , Humans , Manufactured Materials , Neoplasm Recurrence, Local/diagnostic imaging , Radionuclide Imaging , Thyroid Neoplasms/surgeryABSTRACT
OBJECTIVE: In this article, we describe FDG uptake in schwannoma as measured on positron emission tomography (PET). FDG uptake is compared with tumor cellularity, tumor size, and tumor proliferation rate (Ki-67 index). CONCLUSION: Schwannomas generally have a high tumor-to-background ratio on FDG PET. Semiquantitative analysis with standardized uptake values (SUVs) reveals a wide variation in SUVs that can be explained by variations in the degree of cellularity. No correlation was found between FDG uptake and tumor size or tumor proliferation rate (Ki-67 index). Because these tumors often have a high level of FDG uptake, distinguishing schwannomas from malignant peripheral nerve sheath tumors before biopsy or surgery is not possible. Even in cases in which the maximum SUV or average SUV is greater than 6.0, schwannomas cannot be excluded. Therefore, schwannoma should be included in the differential diagnosis of peripheral nerve sheath tumors with low, intermediate, or high SUVs.